# Interleukin-1 Receptor Antagonist and Insulin Sensitivity

> **NCT00928876** · PHASE2 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 12 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Insulin Resistance

## Interventions

- **DRUG:** Anakinra (Kineret)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00928876
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2010-03
- **Final completion:** 2010-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2010-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928876, "Interleukin-1 Receptor Antagonist and Insulin Sensitivity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00928876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*